The whole Zolpimist thing has me somewhat perplexed. It's been on sale in the US for a while now, if successful, surely the prescription data alone would be enough to entice/close a deal. Would like to know prescription/sales data from the States... At least that would give an indication if there was something substantial heading Suda's way or if we are simply chasing a mirage...
Ann: New Analyst Report, page-29
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
-0.005(3.33%) |
Mkt cap ! $152.5M | |||
| Open | High | Low | Value | Volume |
| 14.8¢ | 15.0¢ | 14.3¢ | $303.9K | 2.087M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 202037 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 320045 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ALA (ASX) Chart |